Impact of drug-drug interaction of JAK inhibitors, CYP enzyme inhibitors and OAT3 inhibitors on persistence and infection rates in patients with autoimmune rheumatic diseases.
Janus kinase (JAK) inhibitors are effective treatments for autoimmune rheumatic diseases (AIRDs). However, concomitant use of JAK inhibitors with CYP enzyme inhibitors or OAT3 inhibitors can lead to drug-drug interactions. This study aimed to evaluate the impact of the concomita…